Status:
TERMINATED
Pharmacogenomic Testing in Major Depressive Disorder
Lead Sponsor:
Columbia University
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
21-80 years
Phase:
NA
Brief Summary
This is a two-arm double-blind prospective randomized controlled trial (RCT) to evaluate clinical impact of pharmacogenomic testing on the treatment of major depressive disorder. Participants will be ...
Detailed Description
To a large extent, variability in antidepressant efficacy can be explained by genetic variations that affect medication-metabolizing enzymes, drug transporters, and medication targets. Recent reviews ...
Eligibility Criteria
Inclusion
- Clinical diagnosis of major depressive disorder (MDD)
- Prescription of index antidepressant medications
- Minimum score of 14 on the 17-item Hamilton Rating Scale for Depression (HAMD-17)
Exclusion
- Diagnosis of bipolar disorder (any type), schizophrenia, or schizoaffective disorders
- Active diagnosis of substance abuse or dependence
- Current suicidal ideation
- Previous suicidal attempts
- A person has already had pharmacogenetic testing done.
Key Trial Info
Start Date :
August 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 17 2019
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT03228953
Start Date
August 1 2017
End Date
July 17 2019
Last Update
October 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University Irving Medical Center
New York, New York, United States, 10032